174 related articles for article (PubMed ID: 38292182)
1. Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration.
Qiu X; He H; Zeng H; Tong X; Zhang C; Liu Y; Liao Z; Liu Q
Genes Dis; 2024 May; 11(3):101004. PubMed ID: 38292182
[TBL] [Abstract][Full Text] [Related]
2. MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer.
Jiao M; Zhang F; Teng W; Zhou C
Int J Gen Med; 2022; 15():3003-3030. PubMed ID: 35313552
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer analysis indicates that MYBL2 is associated with the prognosis and immunotherapy of multiple cancers as an oncogene.
Chen X; Lu Y; Yu H; Du K; Zhang Y; Nan Y; Huang Q
Cell Cycle; 2021 Nov; 20(21):2291-2308. PubMed ID: 34585645
[TBL] [Abstract][Full Text] [Related]
4. [High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].
Yang M; Zhu X; Shen Y; He Q; Qin Y; Shao Y; Yuan L; Ye H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1109-1118. PubMed ID: 36073208
[TBL] [Abstract][Full Text] [Related]
5. The hexosamine biosynthesis pathway-related gene signature correlates with immune infiltration and predicts prognosis of patients with osteosarcoma.
Su Z; Wang C; Pan R; Li H; Chen J; Tan J; Tian X; Lin T; Shen J
Front Immunol; 2022; 13():1028263. PubMed ID: 36275679
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
Front Genet; 2022; 13():1017866. PubMed ID: 36699466
[No Abstract] [Full Text] [Related]
7. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
8. Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types.
Dai L; Guo X; Xing Z; Tao Y; Liang W; Shi Z; Hu W; Zhou S; Wang X
BMC Cancer; 2023 Jan; 23(1):102. PubMed ID: 36717836
[TBL] [Abstract][Full Text] [Related]
9. Exploring the relationship between metabolism and immune microenvironment in osteosarcoma based on metabolic pathways.
Wu C; Tan J; Shen H; Deng C; Kleber C; Osterhoff G; Schopow N
J Biomed Sci; 2024 Jan; 31(1):4. PubMed ID: 38212768
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis.
Lv Y; Wu L; Jian H; Zhang C; Lou Y; Kang Y; Hou M; Li Z; Li X; Sun B; Zhou H
Front Immunol; 2022; 13():997765. PubMed ID: 36275664
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic and immunological values of RBM34 in osteosarcoma and its pan-cancer analysis.
Zhang W; He R; Cao W; Li D; Zheng Q; Zhang Y
Am J Cancer Res; 2023; 13(11):5094-5121. PubMed ID: 38058813
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive pan-cancer analysis identifies a novel glycolysis score and its hub genes as prognostic and immunological biomarkers.
Zheng D; Long S; Xi M
Transl Cancer Res; 2023 Oct; 12(10):2852-2874. PubMed ID: 37969385
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.
Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W
Front Immunol; 2022; 13():994828. PubMed ID: 36405728
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of RAN by MYBL2 maintains osteosarcoma cancer stem-like cells population during heterogeneous tumor generation.
Gao W; Zhou J; Huang J; Zhang Z; Chen W; Zhang R; Kang T; Liao D; Zhong L
Cancer Lett; 2024 Apr; 586():216708. PubMed ID: 38336287
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
17. PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer.
Zhao R; Chen S; Cui W; Xie C; Zhang A; Yang L; Dong H
Front Immunol; 2023; 14():1232047. PubMed ID: 37936713
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
Yang H; Zhao L; Zhang Y; Li FF
Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
